Literature DB >> 3235664

Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.

E J Goldstein1, D M Citron.   

Abstract

The six species of the Bacteroides fragilis group are potent pathogens and commonly have different susceptibility patterns. We determined the relative annual isolation rate of anaerobic bacteria and the susceptibility of B. fragilis group species isolated during 1987 at two community hospitals. The relative frequencies of isolation of 261 strains were as follows: B. fragilis, 61%; B. thetaiotaomicron, 17%; B. distasonis, 7%; B. vulgatus, 6%; B. ovatus, 5%; and B. uniformis, 4%. A total of 234 recent clinical isolates were tested against cefmetazole, cefotetan, cefoxitin, ceftizoxime, clindamycin, imipenem, and piperacillin by a brucella agar dilution method. Imipenem was the most active agent tested with all but three isolates (two B. vulgatus and one B. distasonis) susceptible to less than 2 micrograms/ml. Of the cephalosporins tested, cefoxitin, cefotetan, and cefmetazole were relatively equal against B. fragilis, with 93 to 98% of strains susceptible to 32 micrograms/ml. Ceftizoxime was less active, with an MIC for 90% of strains tested of 128 micrograms/ml and only 75% of isolates susceptible to 32 micrograms/ml. Against B. ovatus, B. vulgatus, B. thetaiotaomicron, and B. uniformis, cefoxitin showed a two- to threefold-superior activity compared with that of cefotetan and cefmetazole. In general, ceftizoxime was much less active, except against B. distasonis, for which 78% of isolates were susceptible to 32 micrograms/ml compared with 68% for cefoxitin, 19% for cefmetazole, and 16% for cefotetan. Clindamycin and piperacillin showed activity similar to that of cefoxitin, except piperacillin was less active versus B. vulgatus and B. distasonis. We therefore suggest that clinical laboratories determine the species of B. fragilis group isolates as well as perform susceptibility studies on the isolates. Clinicians should be aware that while B. fragilis is the most frequent isolate, 38% of isolates are from other, more resistant B. fragilis group species.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3235664      PMCID: PMC266893          DOI: 10.1128/jcm.26.11.2361-2366.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria.

Authors:  V L Sutter; A L Barry; T D Wilkins; R J Zabransky
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

2.  Establishment of MICs of moxalactam for control and reference anaerobic organisms in agar dilution and microdilution techniques.

Authors:  V L Sutter; J Emmerman; E Randall; R J Zabransky; R J Birk
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

3.  Establishment of minimum inhibitory concentrations of cefoperazone for control and reference anaerobic organisms.

Authors:  R J Zabransky; E Randall; V L Sutter; R J Birk; G Westenfelder; J Emmerman; A T Ghoneim
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

4.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  Cefotetan: in-vitro antibacterial activity and susceptibility to beta-lactamases.

Authors:  I Phillips; A King; K Shannon; C Warren
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

6.  Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

7.  Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of Bacteroides species.

Authors:  K E Aldridge; C V Sanders; A Janney; S Faro; R L Marier
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

8.  Six-year retrospective survey of the resistance of Bacteroides fragilis group species to clindamycin and cefoxitin.

Authors:  H M Wexler; B Harris; W T Carter; S M Finegold
Journal:  Diagn Microbiol Infect Dis       Date:  1986-03       Impact factor: 2.803

9.  Comparative in vitro activity of ceftizoxime, cefoperazone, and cefoxitin against anaerobic bacteria.

Authors:  M W Drulak; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Recovery of anaerobic bacteria from clinical specimens in 12 years at two military hospitals.

Authors:  I Brook
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

View more
  16 in total

1.  Occurrence of Bacteroides fragilis enterotoxin gene-carrying strains in Germany and the United States.

Authors:  M C Claros; Z C Claros; Y J Tang; S H Cohen; J Silva; E J Goldstein; A C Rodloff
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

2.  Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Authors:  E J Goldstein; D M Citron; C Vreni Merriam; Y Warren; K L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Susceptibilities of members of the Bacteroides fragilis group to 11 antimicrobial agents.

Authors:  R Horn; J Lavallée; H G Robson
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

4.  Spiral gradient endpoint method compared to standard agar dilution for susceptibility testing of anaerobic gram-negative bacilli.

Authors:  G B Hill
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

5.  National hospital survey of anaerobic culture and susceptibility testing methods: results and recommendations for improvement.

Authors:  E J Goldstein; D M Citron; R J Goldman
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

Review 6.  Ceftizoxime: a third-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors: 
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

7.  Short prereduced anaerobically sterilized (PRAS) biochemical scheme for identification of clinical isolates of bile-resistant Bacteroides species.

Authors:  D M Citron; E J Baron; S M Finegold; E J Goldstein
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

8.  Antimicrobial Stewardship Opportunities in Patients with Bacteremia Not Identified by BioFire FilmArray.

Authors:  P Ny; A Ozaki; J Pallares; P Nieberg; A Wong-Beringer
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

9.  Five-year retrospective epidemiological survey of anaerobic bacteraemia in a university hospital and rewiew of the literature.

Authors:  E Urbán
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-06-13

10.  Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.

Authors:  E J Goldstein; D M Citron; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.